CVRx, Inc. (CVRX)
| Market Cap | 197.70M |
| Revenue (ttm) | 56.65M |
| Net Income (ttm) | -53.31M |
| Shares Out | 26.43M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 145,631 |
| Open | 7.60 |
| Previous Close | 7.65 |
| Day's Range | 7.45 - 7.79 |
| 52-Week Range | 4.30 - 11.30 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 10.50 (+40.37%) |
| Earnings Date | May 11, 2026 |
About CVRX
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its... [Read more]
Financial Performance
In 2025, CVRx, Inc.'s revenue was $56.65 million, an increase of 10.45% compared to the previous year's $51.29 million. Losses were -$53.31 million, -11.10% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price target is $10.5, which is an increase of 40.37% from the latest price.
News
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neurom...
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for pa...
CVRx, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises CVRx , Inc , (“ CVRx " or the "Company") ( NASDAQ : CVRX) investors that the firm has initiated an investigation into poss...
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for pa...
CVRx, Inc. Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw revenue growth and margin improvement, driven by sales force expansion and foundational investments. The transition to Category I CPT codes and the launch of the BENEFIT-HF trial are expected to accelerate growth and expand the addressable market in 2026 and beyond.
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
MINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx Kicks Off One Of The Largest Heart Device Trials In History
CVRx, Inc. (NASDAQ: CVRX) on Thursday initiated the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim in a...
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
Study is Expected to Be One of the Largest Therapeutic Cardiac Device Trials in Heart Failure Ever Performed, and is Supported by CMS Category B IDE Coverage Study is Expected to Be One of the Largest...
CVRx, Inc. Transcript: 44th Annual J.P. Morgan Healthcare Conference
Barostim addresses a large, underserved heart failure market with strong clinical evidence and improved reimbursement, driving double-digit revenue growth and expanding its addressable market through a major new trial. Execution now focuses on salesforce productivity and deeper adoption.
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
MINNEAPOLIS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx, Inc. Transcript: Piper Sandler 37th Annual Healthcare Conference
A major sales force transformation has set the stage for higher productivity, with new reps targeting $1.8 million in annual revenue per territory. Improved reimbursement, robust clinical evidence, and a large-scale RCT are expected to drive adoption and expand the addressable market.
CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference
MINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx, Inc. Transcript: Jefferies London Healthcare Conference 2025
A novel neuromodulation therapy for heart failure is showing strong clinical and real-world results, with significant improvements in quality of life and reduced hospitalizations. Strategic focus on high-opportunity centers and new reimbursement codes are expected to drive adoption and revenue growth.
CVRx, Inc. Earnings Call Transcript: Q3 2025
Q3 2025 saw 10% revenue growth, margin expansion to 87%, and improved sales rep productivity. Guidance for 2025 was narrowed, with mid-teens growth targeted for 2026 as new reimbursement and sales initiatives take effect. Clinical trial expansion and strong cash position support future growth.
CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025
MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx, Inc. Transcript: Canaccord Genuity’s 45th Annual Growth Conference
Barostim therapy targets a large, underserved heart failure market, showing strong clinical and real-world outcomes. Commercial execution is focused on sales force optimization and reimbursement wins, with financial stability and a major trial planned.
CVRx, Inc. Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 15% year-over-year to $13.6 million, driven by U.S. heart failure business and expansion of implanting centers. Gross margin remained strong at 84%, while net loss was $14.7 million. Full-year revenue guidance was narrowed to $55–$57 million.
CVRx Reports Second Quarter 2025 Financial and Operating Results
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) ...
CVRx, Inc. Transcript: 45th Annual William Blair Growth Stock Conference
Barostim targets a $2.2B heart failure market with strong clinical results, including significant quality of life improvements and reduced hospitalizations. The company is transforming its salesforce, focusing on high-potential centers, and expects mid to high 20% long-term growth as reimbursement and access improve.
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod...
CVRx, Inc. Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 15% year-over-year to $12.3 million, but sales force realignment and seasonality impacted results. Management expects productivity to improve as new hires ramp up, with full-year revenue guidance set at $55–$58 million and robust clinical evidence supporting Barostim adoption.